ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jaybe	6/22/2016 9:17:15 PM
	Read Replies (2) of 4474

MSKCC finds synergy with pona and trametinib in KRASm lung cancer... "We next tested whether therapeutic strategies combining trametinib with an FGFR1 inhibitor could be effective in treating some KRAS- mutant lung cancers by combining trametinib with ponatinib, an FDA-approved multikinase inhibitor that inhibits FGFR1 and is being tested clinically for activity against FGFR1-amplified lung cancer. Ponatinib had little effect on KRAS-mutant cells but countered the trametinib-induced increase in pFRS2, pERK, and pAKT, and synergized with trametinib in inhibiting cell proliferation. As observed in our genetic studies, this combination also showed combined activity in human KRAS-mutant pancreatic cancer cells and a Kras-mutant murine lung adenocarcinoma line, but to a lesser extent in KRAS wild-type lung cancer cells or KRAS- mutant colon cancer cells." nature.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next